GILD
GILEAD SCIENCES, INC.Marquee-fund ownership over time
This quarter's activity
New positions opened
Positions exited
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Bridgewater Associates re-entered | Q1 2014 | 50Q | $57 | $130 | +129% |
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $70 | $130 | +85% |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $70 | $130 | +84% |
| Two Sigma Investments re-entered | Q3 2024(8Q snapshot) | 7Q | $70 | $130 | +84% |
| D.E. Shaw | Q3 2024(8Q snapshot) | 7Q | $70 | $130 | +84% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $70 | $130 | +84% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $70 | $130 | +84% |
| Point72 Asset Management re-entered | Q3 2024(8Q snapshot) | 7Q | $70 | $130 | +84% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Maverick Capital 3× in & out | Q4 2020 | Q2 2021 | → $57 | +16% |
| Duquesne Family Office 3× in & out | Q3 2018 | Q2 2019 | → $50 | -13% |
| Third Point | Q4 2013 | Q2 2014 | → $55 | +16% |
| Viking Global Investors | Q3 2013 | Q4 2013 | → $48 | +19% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at GILEAD SCIENCES, INC.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 2, 2026 — the most recent Form 4 on file — not from today.
- Form 40001638643-26-000022Jun 2, 2026
- Form 40001123292-26-000751May 27, 2026
- Form 40001310204-26-000016May 18, 2026
- Form 40001782135-26-000016May 18, 2026
- Form 40000882095-26-000010May 4, 2026
- Form 40001183680-26-000002May 4, 2026
- Form 40001638709-26-000002May 4, 2026
- Form 40001188919-26-000004May 4, 2026
- Form 40001415548-26-000003May 4, 2026
- Form 40001213307-26-000003May 4, 2026
- Form 40001527726-26-000002May 4, 2026
- Form 40001629885-26-000002May 4, 2026
- Form 40001638643-26-000020Apr 29, 2026
- Form 40001310204-26-000014Apr 16, 2026
- Form 40001782135-26-000014Apr 16, 2026
Fundamentals
XBRL · GILEAD SCIENCES, INC.Annual figures sourced directly from GILEAD SCIENCES, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for GILEAD SCIENCES, INC. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KFORM 8-KMay 20, 2026
- 10-QFORM 10-QMay 7, 2026
- 8-KFORM 8-KMay 7, 2026
- 8-KFORM 8-KMay 4, 2026
- 8-KFORM 8-KApr 28, 2026
- DEF 14ADEFINITIVE PROXY STATEMENTMar 20, 2026
- 10-KFORM 10-KFeb 24, 2026
- 8-KFORM 8-KFeb 23, 2026
- 8-KFORM 8-KFeb 10, 2026
- 8-KFORM 8-KNov 19, 2025
- 10-QFORM 10-QNov 7, 2025
- 8-KFORM 8-KOct 30, 2025
- 8-KFORM 8-KOct 6, 2025
- 8-KFORM 8-KAug 14, 2025
- 10-QFORM 10-QAug 7, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Two Sigma Investments | Q2 2026 | open | $130 | $130 | +0% |
| Point72 Asset Management | Q2 2026 | open | $130 | $130 | +0% |
| Citadel Advisors | Q3 2024 | open | $70 | $130 | +84% |
| Two Sigma Investments | Q3 2024 | Q3 2025 | $70 | $117 | +66% |
| D.E. Shaw | Q3 2024 | open | $70 | $130 | +84% |
| AQR Capital Management | Q3 2024 | open | $70 | $130 | +84% |
| Millennium Management | Q3 2024 | open | $70 | $130 | +84% |
| Point72 Asset Management | Q3 2024 | Q4 2025 | $70 | $123 | +75% |
| Renaissance Technologies | Q3 2024 | open | $70 | $130 | +85% |
| Bridgewater Associates | Q1 2021 | open | $55 | $128 | +134% |
| Maverick Capital | Q4 2020 | Q2 2021 | $50 | $57 | +16% |
| Maverick Capital | Q4 2019 | Q2 2020 | $50 | $61 | +22% |
| Duquesne Family Office | Q3 2018 | Q2 2019 | $58 | $50 | -13% |
| Bridgewater Associates | Q3 2018 | Q1 2020 | $58 | $53 | -9% |
| Maverick Capital | Q2 2015 | Q4 2017 | $76 | $52 | -31% |
| Duquesne Family Office | Q4 2014 | Q1 2015 | $71 | $70 | -1% |
| Bridgewater Associates | Q1 2014 | Q2 2017 | $57 | $48 | -15% |
| Third Point | Q4 2013 | Q2 2014 | $48 | $55 | +16% |
| Viking Global Investors | Q3 2013 | Q4 2013 | $40 | $48 | +19% |
| Duquesne Family Office | Q3 2013 | Q2 2014 | $40 | $56 | +39% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.